A Randomized, Double Blind, Placebo Controlled Phase II Trial to Evaluate the Safety and Efficacy of recMAGE-A3 + AS15 ASCI in Patients With MAGE-A3 Positive Muscle Invasive Bladder Cancer After Cystectomy

Trial Profile

A Randomized, Double Blind, Placebo Controlled Phase II Trial to Evaluate the Safety and Efficacy of recMAGE-A3 + AS15 ASCI in Patients With MAGE-A3 Positive Muscle Invasive Bladder Cancer After Cystectomy

Discontinued
Phase of Trial: Phase II

Latest Information Update: 19 Jun 2017

At a glance

  • Drugs Zastumotide (Primary) ; AS15
  • Indications Bladder cancer
  • Focus Therapeutic Use
  • Acronyms MAGNOLIA
  • Most Recent Events

    • 15 Jun 2017 Status changed from active, no longer recruiting to discontinued.
    • 26 Apr 2017 This trial has been completed in Netherland as per European Clinical Trials Database record.
    • 20 Mar 2017 This trial has been completed in Germany.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top